Herantis Pharma to participate in Bio-Europe Spring and AD/PD 2023

Herantis Pharma Plc, Press Release, 9 March 2023 at 09:00 A.M. EET

Herantis Pharma Plc (“Herantis”), developing disease-modifying therapies for Parkinson’s disease, today announced participation in the following conferences:

Bio-Europe Spring

Location: Basel, Switzerland

Dates: March 20th – 22nd, 2023

Attendees: CEO Antti Vuolanto, DSc and CSO Dr. Henri Huttunen, PhD

AD/PD 2023: International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders

Location: Gothenburg, Sweden

Dates: March 28th – April 1th, 2023

  1. Poster Presentation by Head of Nonclinical Pharmacology at Herantis, Natalia Kulesskaya, PhD.

Title: HER-096 Is a Novel Brain-Penetrating Peptidomimetic That Promotes Proteostasis and Reduces Neuroinflammation in Aged Mouse Model of Synucleinopathy

  1. Presentation by Per Svenningsson, MD, PhD, Karolinska University Hospital, Principal Investigator of Herantis’ CDNF in the First-in-Human Clinical Trial.

Title: Phase 1 First-in-Man Clinical Trial of Intraputamenal CDNF in Parkinson’s Disease

If you want to learn more about Herantis and our asset HER-096, you can contact the conference organizers or connect with us directly at ir@herantis.com.

For more information, please contact:

Julie Silber/Gabriela Urquilla

Tel: +46 (0)7 93 486 277/+46 (0)72-396 72 19

Email: ir@herantis.com

Certified Advisor: UB Securities Ltd, Finland: +358 9 25 380 225

About Herantis Pharma Plc

Herantis Pharma Plc is an innovative biotech company developing disease modifying therapies for Parkinson’s disease. Herantis’ lead product HER-096, is an advanced small synthetic chemical peptidomimetic molecule developed based on the active site of the parent CDNF protein. It combines the compelling mechanism of action of the CDNF protein with the convenience of subcutaneous administration. The shares of Herantis are listed on the Nasdaq First North Growth Market Finland.

Company website: www.herantis.com